PHARMA DEALS DURING MAY 2014
(Part 3 out of 3)

In May, the deals announced by Big Pharma companies to streamline and rationalise their business operations continued apace with a high level of M&A activity.  The deals mentioned represent the valued deals that were announced during May but there were two major M&A offers that did not materialise in the month. Firstly, the Pfizer bid for AstraZeneca and, secondly, the Valeant bid for Allergan. 

This table lists all the major pharma collaborations, acquisitions and mergers agreed during May 2014

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Merck & Co OTC Business / Bayer	Asset / product acquisition	Consumer care business incl. Claritin, Afrin and Coppertone brands	14,200
CFR Pharmaceuticals / Abbott	Company acquisition	Chile-based branded generic company with Latin America (2013 sales  $768m)	3,330
Bayer / Merck & Co	Co-development and co-commercialisation	Soluble guanylate cyclase modulators for cardiovascular disease	2,100
Valeant / Nestle	Asset / product acquisition	Injectable cosmetic fillers for facial wrinkles including Dysport	1,400
Ophthotech / Novartis	Commercialisation1and co-development licence	Fovista (start p3) for treatment of wet age-related macular degeneration	1,030
Chelsea / Lundbeck	Company acquisition	US company with treatments for rare neurologic diseases	658
Avalanche / Regeneron	Development and commercialisation licence	Gene therapy products for ophthalmologic disease	653
Merck & Co / Santen	Asset / product acquisition2	Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m	600+
MacroGenics / Takeda	Option to license end p1a to develop and commercialise	MGD010, a preclinical bispecific antibody for treatment of auto-immune disease	502
VersaPharm / Akorn	Company acquisition	US generic company selling dermatology products with $100m sales	440
Bayer Interventional Device Business / Boston Scientific	Asset / product acquisition	Devices for coronary and peripheral vascular disease (2013 sales $120m)	415
CytomX / BMS	Development and commercialisation licence	Selective monoclonal antibodies (“Probodies”) for up to 4 oncology targets	348
Bedford Labs (Boehringer Ingelheim) / Hikma	Asset / product acquisition	US generic injectable manufacturer and products (2013 sales $19m)	300
GSK product / Pernix	Asset / product acquisition3	Marketed sumatriptan/naproxen combination. 2013 sales $79m	267
Lumena / Shire	Company acquisition	US company with late stage compounds for treatment of rare GI / hepatic diseases	260+
Xenoport / Reckitt Benckiser	Development and commercialisation licence	Arbaclofen placarbil end pIIa for alcohol use disorders	145
Neurotez / GCA Therapeutics	Development and commercialisation licence4	Leptin derivatives for treatment of cognitive disorders	103
Fibrotech / Shire	Company acquisition	Australian company with pIb product for rare fibrotic kidney disease	75+
Ligand / Omthera (AstraZeneca)	Research, development and commercialisation licence	Omthera's prodrug delivery platform for omega-3  fatty acids for dyslipidaemia	45
Viking / Ligand	Licence to develop. Ligand provides $2.5m loan	Five development small molecule programmes. Lead product pIIb type 2 diabetes	N/D
AntiOp / Reckitt Benckiser	Supply and marketing agreement	Intranasal naloxone for opioid abuse in late clinical development	N/D

All deals are worldwide unless otherwise noted.

¹ - Ex-US

² - Japan and key markets in Europe and Asia Pacific

³ - US

⁴ - China 

Fuente: PMLive

Haciendo click en los links siguientes, accederán a los Contenidos de algunos de nuestros CURSOS DE CAPACITACIÓN IN COMPANY A MEDIDA:

IN COMPANY - Programa Ejecutivo en PENSAMIENTO ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_6246.html

IN COMPANY - Programa Ejecutivo en MANAGEMENT ESTRATÉGICO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa_3.html

IN COMPANY - Programa Ejecutivo en GESTIÓN DEL CAMBIO

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-programa.html

IN COMPANY - Taller de ESTRATEGIAS EFECTIVAS 

para Escenarios Turbulentos

http://msg-latam-meic.blogspot.com.ar/2014/06/capacitacion-in-company-taller-de.html

Consultas al mail: msg.latam@gmail.com

ó al TE: +5411-3532-0510